# Braveheart Bio initial public offering

> Live situation record from CLSTR: https://clstr.news/situations/braveheart-bio-initial-public-offering
> Updated: 2026-08-08T11:07:52.000Z. Sources: 4. Developments: 2.

Braveheart Bio Inc., a biopharmaceutical company focused on therapeutics for hypertrophic cardiomyopathy and other cardiovascular diseases, initiated its initial public offering on the Nasdaq Global Market. The company upsized its offering to 21,250,000 common shares priced at $18.00 per share, aiming to raise approximately $382.5 million in gross proceeds.

Following the completion of the $382 million IPO, company executives and directors engaged in significant insider stock purchases. These acquisitions included approximately $500,000 worth of shares by CFO James Paul Rickey and approximately $1 million worth of shares by director David Charles Lubner, both at the $18.00 per share price.

## Timeline

### 2026-08-08: Braveheart Bio completes $382M IPO amid insider stock purchases

Braveheart Bio completed a $382 million IPO for its heart disease drug candidate, while CFO and directors engaged in significant insider stock purchases.

2 sources. https://clstr.news/cluster/braveheart-bio-completes-382m-ipo-amid-insider-stock-purchases

### 2026-08-06: Braveheart Bio Prices Upsized $18 IPO, Set to List on Nasdaq Aug. 6

Braveheart Bio priced an upsized $18 IPO of 21.25 M shares, expecting $382.5 M proceeds, with trading on Nasdaq (BRVE) set for Aug 6, 2026.

2 sources. https://clstr.news/cluster/braveheart-bio-prices-upsized-18-ipo-set-to-list-on-nasdaq-aug-6

---
Cite as: Braveheart Bio initial public offering. CLSTR, https://clstr.news/situations/braveheart-bio-initial-public-offering